IL-33 reduces the development of atherosclerosis

Journal of Experimental Medicine

Volumn 205, Issue 2, 2008, Pages 339-346

  Miller, Ashley M ^a   Xu, Damo ^a   Asquith, Darren L ^a   Denby, Laura ^b   Li, Yubin ^a   Sattar, Naveed ^b   Baker, Andrew H ^b   McInnes, Iain B ^a   Liew, Foo Y ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOENZYME; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 13; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 5; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN; ST2 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA SINUS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; IMMUNOGLOBULIN BLOOD LEVEL; LYMPH NODE CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL; VASCULARIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; AORTA, THORACIC; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELLS, CULTURED; CYTOKINES; DIET, ATHEROGENIC; ENDOTHELIAL CELLS; HUMANS; IMMUNOGLOBULINS; INTERLEUKIN-5; INTERLEUKINS; LIPOPROTEINS, LDL; MACROPHAGES; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCYTES, SMOOTH MUSCLE; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 39549100797     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20071868     Document Type: Article

References (30)

1. Hansson, G.K., and P. Libby, 2006, The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 6:508-519.
2. Salonen, J.T., S. Yla-Herttuala, R. Yamamoto, S. Butler, H. Korpela, R. Salonen, K. Nyyssonen, W. Palinski, and J.L. Witztum, 1992, Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet, 339:883-887.
3. Major, A.S., S. Fazio, and M.F. Linton, 2002, B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler. Thromb. Vasc. Biol. 22:1892-1898.
4. Caligiuri, G., A. Nicoletti, B. Poirier, and G.K. Hansson, 2002, Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J. Clin. Invest. 109:745-753.
5. de Boer, O.J., A.C. van der Wal, C.E. Verhagen, and A.E. Becker, 1999, Cytokine secretion profiles of cloned T cells from human aortic atherosclerotic plaques. J. Pathol. 188:174-179.
6. Zhou, X., A. Nicoletti, R. Elhage, and G.K. Hansson, 2000, Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation, 102:2919-2922.
7. Davenport, P., and P.G. Tipping, 2003, The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am. J. Pathol. 163:1117-1125.
8. -/-) mice through release of interferon-gamma. Circ. Res. 90:E34-E38.
9. Gupta, S., A.M. Pablo, X. Jiang, N. Wang, A.R. Tall, and C. Schindler, 1997, IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J. Clin. Invest. 99:2752-2761.
10. Buono, C., C.J. Binder, G. Stavrakis, J.L. Witztum, L.H. Glimcher, and A.H. Lichtman, 2005, T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc. Natl. Acad. Sci. USA, 102:1596-1601.
11. Binder, C.J., K. Hartvigsen, M.K. Chang, M. Miller, D. Broide, W. Palinski, L.K. Curtiss, M. Corr, and J.L. Witztum, 2004, IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J. Clin. Invest. 114:427-437.
12. Schmitz, J., A. Owyang, E. Oldham, Y. Song, E. Murphy, T.K. McClanahan, G. Zurawski, M. Moshrefi, J. Qin, X. Li, et al, 2005, IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity, 23:479-490.
13. Xu, D., W.L. Chan, B.P. Leung, F. Huang, R. Wheeler, D. Piedrafita, J.H. Robinson, and F.Y. Liew, 1998, Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J. Exp. Med. 187:787-794.
14. Weinberg, E.O., M. Shimpo, S. Hurwitz, S. Tominaga, J.L. Rouleau, and R.T. Lee, 2003, Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation, 107:721-726.
15. Shimpo, M., D.A. Morrow, E.O. Weinberg, M.S. Sabatine, S.A. Murphy, E.M. Antman, and R.T. Lee, 2004, Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation, 109:2186-2190.
16. Sanada, S., D. Hakuno, L.J. Higgins, E.R. Schreiter, A.N. McKenzie, and R.T. Lee, 2007, IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117:1538-1549.
17. Tedgui, A., and Z. Mallat, 2006, Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol. Rev. 86:515-581.
18. Carriere, V., L. Roussel, N. Ortega, D.A. Lacorre, L. Americh, L. Aguilar, G. Bouche, and J.P. Girard, 2007, IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc. Natl. Acad. Sci. USA, 104:282-287.
19. Lohning, M., A. Stroehmann, A.J. Coyle, J.L. Grogan, S. Lin, J.C. Gutierrez-Ramos, D. Levinson, A. Radbruch, and T. Kamradt, 1998, T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc. Natl. Acad. Sci. USA, 95:6930-6935.
20. Hashmi, S., and Q.T. Zeng, 2006, Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron. Artery Dis. 17:699-706.
21. Schieffer, B., T. Selle, A. Hilfiker, D. Hilfiker-Kleiner, K. Grote, U.J. Tietge, C. Trautwein, M. Luchtefeld, C. Schmittkamp, S. Heeneman, et al, 2004, Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation, 110:3493-3500.
22. Tous, M., V. Ribas, J.C. Escola-Gil, F. Blanco-Vaca, L. Calpe-Berdiel, B. Coll, N. Ferre, C. Alonso-Villaverde, A. Rull, J. Camps, et al, 2006, Manipulation of inflammation modulates hyperlipidemia in apolipoprotein E-deficient mice: a possible role for interleukin-6. Cytokine, 34:224-232.
23. Ait-Oufella, H., B.L. Salomon, S. Potteaux, A.K. Robertson, P. Gourdy, J. Zoll, R. Merval, B. Esposito, J.L. Cohen, S. Fisson, et al, 2006, Natural regulatory T cells control the development of atherosclerosis in mice. Nat. Med. 12:178-180.
24. Takatsu, K. 1998, Interleukin 5 and B cell differentiation. Cytokine Growth Factor Rev. 9:25-35.
25. Horkko, S., D.A. Bird, E. Miller, H. Itabe, N. Leitinger, G. Subbanagounder, J.A. Berliner, P. Friedman, E.A. Dennis, L.K. Curtiss, et al, 1999, Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest. 103:117-128.
26. Hulthe, J. 2004, Antibodies to oxidized LDL in atherosclerosis development - clinical and animal studies. Clin. Chim. Acta, 348:1-8.
27. Komai-Koma, M., D. Xu, Y. Li, A.N. McKenzie, I.B. McInnes, and F.Y. Liew, 2007, IL-33 is a chemoattractant for human Th2 cells. Eur. J. Immunol. 37:2779-2786.
28. Sweet, M.J., B.P. Leung, D. Kang, M. Sogaard, K. Schulz, V. Trajkovic, C.C. Campbell, D. Xu, and F.Y. Liew, 2001, A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J. Immunol. 166:6633-6639.
29. Nicklin, S.A., H. Buening, K.L. Dishart, M. de Alwis, A. Girod, U. Hacker, A.J. Thrasher, R.R. Ali, M. Hallek, and A.H. Baker, 2001, Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4:174-181.
30. Daugherty, A., and S.C. Whitman, 2003, Quantification of atherosclerosis in mice. Methods Mol. Biol. 209:293-309.